Cazzolla Angela Pia, Troiano Giuseppe, Zhurakivska Khrystyna, Maiorano Eugenio, Favia Gianfranco, Lacaita Maria Grazia, Marzo Giuseppe, Dicuonzo Franca, Andresciani Stefano, Muzio Lorenzo Lo
Department of Translational Medicine, University of Bari, Bari, Italy.
Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
J Med Case Rep. 2017 May 9;11(1):130. doi: 10.1186/s13256-017-1286-3.
Langerhans cell histiocytosis is a sporadic disease caused by an uncontrolled pathogenic clonal proliferation of dendritic cells that have Langerhans cell characteristics. New treatment protocols provided by the HISTSOC-LCH-III (NCT00276757) trial show an improvement in the survival of children with langerhans cell histiocytosis.
We report a case of Langerhans cell histiocytosis, which presented as an osteolytic lesion of the left pre-maxillae enclosing the deciduous incisor and canine in a 7-month-old white Italian boy. He was treated with chemotherapy. He achieved complete remission after 7 months and after 24 months no signs of recurrence were observed.
As a result of this treatment, anesthetic sequelae and loss of teeth were avoided; in addition, we prevented a loss of the vertical dimension of occlusion.
朗格汉斯细胞组织细胞增多症是一种由具有朗格汉斯细胞特征的树突状细胞不受控制的致病性克隆增殖引起的散发性疾病。HISTSOC-LCH-III（NCT00276757）试验提供的新治疗方案显示，朗格汉斯细胞组织细胞增多症患儿的生存率有所提高。
我们报告一例朗格汉斯细胞组织细胞增多症病例，该病例表现为一名7个月大的意大利白人男孩左上颌前部的溶骨性病变，包绕乳切牙和尖牙。他接受了化疗。7个月后实现完全缓解，24个月后未观察到复发迹象。
通过这种治疗，避免了麻醉后遗症和牙齿缺失；此外，我们防止了咬合垂直距离的丧失。
Zotero 插件
